Podcast appearances and mentions of adam numis

This week on Seizing Life® kids who either have epilepsy or who have family members with epilepsy ask pediatric neurologists about epilepsy. Dr. Kristen Park of Children's Hospital of Colorado and Dr. Adam Numis of the UCSF Benioff Children's Hospital answer questions on a wide variety of topics related to epilepsy in an episode recorded live at Epilepsy Awareness Day at Disneyland this past November. The post Kids Ask Docs the Darndest Things About Epilepsy appeared first on CURE Epilepsy.

This week on Seizing Life® kids ask pediatric neurologists about epilepsy. Dr. Kristen Park of Children's Hospital of Colorado and Dr. Adam Numis of the UCSF Benioff Children's Hospital answer questions from kids on a wide variety of topics related The post Kids Ask Docs the Darndest Things About Epilepsy appeared first on CURE Epilepsy.

Twenty-five percent of children who survive acute symptomatic seizures as neonates go on to develop epilepsy. Whilst there are several known risk factors, currently not enough is known about the mechanisms behind the development of epilepsy following neonatal brain injury, and thus it is not yet possible to reliably predict the individual risk of developing this disease in this group of patients.In this episode, we speak to Adam Numis from UC San Francisco. He and his team used whole exome sequencing with targeted gene analysis to look for genetic risk factors for developing epilepsy following acute neonatal seizures, and to identify potential biological processes behind this epileptogenesis. Read the study here. See acast.com/privacy for privacy and opt-out information.

A number of clinical variables are used to predict the likelihood of childhood epilepsy, however, additional predictors are needed to improve patient stratification for those at the highest risk of recurrent seizures. In this episode, we meet Adam Numis from the University of California San Francisco, who set out to assess the utility of circulating cytokines as a predictor of childhood epilepsy. He performed a longitudinal study of newborns at risk of neonatal encephalopathy, revealing an association between circulating levels of particular inflammatory cytokines and the later development of epilepsy. See acast.com/privacy for privacy and opt-out information.

1) Featured Article: Quality improvement in neurology: Child neurology quality measure set2) Lesson of the Week: Update on chronic migraine risk factors, management, and treatmentThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 9, 2018, issue of Neurology. In the first segment, Dr. Adam Numis talks with Dr. Jeffrey Buchhalter and Dr. Anup Patel about their quality measure set executive summary article regarding child neurology. For the “Lesson of the Week” segment, Dr. Tesha Monteith speaks with Dr. Stephen Silberstein about chronic migraine.DISCLOSURES:Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section; has received speaker honorarium from LivaNova; and has received research support from American Academy of Neurology, Clinical Research Training Fellowship in Epilepsy, 2017-2019, and American Epilepsy Society, Research and Training Fellowships for Clinicians, 2017-2018.Dr. Bucchalter has served on advisory and safety monitoring boards for NIH, NINDS, Observational Safety Monitoring Board for NIH, and the Charlie Foundation; has received travel and speaker honoraria from AAN, Eisai Co. Ltd., Child Neurology Society, Lundbeck, and Upsher-Smith Labs; serves on the editorial board for Pediatric Neurology; has consulted in the past with Lundbeck Inc., Eisai Co. Ltd., UCB, and Upsher-Smith; and has received research support from Alberta Health Services.Dr. Patel has served on scientific advisory board for UCB Pharma; has served as book and associate editor for Journal of Child Neurology; has consulted for Greenwich Biosciences, LivaNova, and Supernus; and has received research support from Greenwich Biosciences, Brain Sentinel, Upsher Smith Pharmaceuticals, LivaNova, Pediatric Epilepsy Research Foundation (PERF), and American Academy of Neurology (AAN).Dr. Silberstein has served on scientific advisory boards for Alder, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Mitsubishi Tanabe, Neuralieve, NINDS, Pfizer, Supernus, Teva, Curelator, Depomed, Dr. Reddy's Laboratories, Lilly, and Trigemina; has served on editorial boards for Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management, and Neurology; has consulted for Allergan, Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Neuralieve, Pfizer, Supernus, and Teva; served on speaker's bureaus in the past for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck; and has received research support from GlaxoSmithKline, Allergan, Merck, Novartis, NIH, Neurolieve, MAP, Endo, Amgen, ElectroCore, Avanir, NIH, AHS, and IHS.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.

1) Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis2) e-Pearl topic: Hemiplegic migraine3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Adam Numis interviews Dr. David Gloss about this AAN Practice Advisory paper on the utility of EEG theta and beta power ration in attention deficit hyperactivity disorder diagnosis. Dr. Ilena George is reading our e-Pearl of the week about hemiplegic migraine. In the next part of the podcast Dr. Alberto Espay interviews Dr. Steven Frucht on the topic of “how to approach” myoclonus.DISCLOSURES: Dr. Numis served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gloss serves on the Level of evidence team for Neurology®; is an Evidence-based medicine consultant for the American Academy of Neurology; receives royalties from the publication of the book Neurology for the Specialty Boards.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Frucht serves as Editor-in-Chief for the Journal of Clinical Movement Disorders; is a consultant for UCB; received speaker honoraria from Merz Pharmaceuticals, LLC and Impax; receives royalties from the publication of the book Movement Disorders Emergencies; and is employed by the American Academy of Neurology Movement Disorders Society.

1) Editorial Titled: The Terrorist inside My Husband's Brain2) e-Pearl topic: X-linked myopathy with excessive autophagy3) Topic of the month: Neurologic prognosis following cardiac arrestThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mrs. Susan Schneider Williams about her editorial on learning to deal with her husband's (Robin Williams) Lewy Body disease. Dr. Adam Numis is reading our e-Pearl of the week about X-linked myopathy with excessive autophagy. In the next part of the podcast Dr. Andy Schomer concludes his interview with Dr. Eelco Wijdicks about prognostic models and clinical findings of myoclonus.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Mrs. Schneider Williams serves on the board of directors for the American Brain Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks receives royalties from the publication of several books.

1) Influence of sodium consumption and associated knowledge on post-stroke hypertension in Uganda2) e-Pearl topic: Transient cerebral arteriopathy3) Topic of the month: Neurologic prognosis following cardiac arrestThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Larry Goldstein about his paper on the influence of sodium consumption and its associated knowledge on post-stroke patients with and without a history of hypertension in Uganda. Dr. Adam Numis is reading our e-Pearl of the week about transient cerebral arteriopathy. In the next part of the podcast Dr. Andy Schomer continues his interview with Dr. Eelco Wijdicks about the ancillary testing that is done in patients with cardiac arrest.DISCLOSURES: Dr. Goldstein serves as an editorial board member of Neurology®, Emergency Medicine, Cardiology Today and Stroke; serves as an Associate Editor for Cerebrovascular Diseases; serves on the scientific advisory board for Daichi Sanyo, Merz, Roche and Pfizer Inc; is a consultant for Artemida, Nestle and Stroke Hospitalization in Elderly with Medicare; receives honoraria from serving on the scientific advisory board of Pfizer Inc; receives royalties from the publication of the books: Screening for Asymptomatic Carotid Stenosis, Use and Utility of Stroke Scales and Grading Sysytems and Henry Stewart Talks, Secondary Stroke Prevention; receives research support from Stroke Hospitalization in Elderly with Medicare and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks receives royalties from the publication of several books.

1) APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline 2) e-Pearl topic: Ocular neuromyotonia3) Topic of the month: Neurology Today story about Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 2)This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Prof. Martha Morris about her paper on APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. Dr. Adam Numis is reading our e-Pearl of the week about ocular neuromyotonia. Dr. Ted Burns interviews Dr. Gary Franklin about a Neurology Today story on the topic of the new Center for Disease Control guidelines on prescribing opioids (Part 2).DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Prof. Morris is a consultant for Neurotrack; serves on the scientific advisory board for the University of Chicago; received funding for travel from the University of California; receives research support from the Abbott Fund and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Franklin serves as an editorial board member of Neuroepidemiology; serves on the Levels of Evidence Team for Neurology®; is a consultant for the California State Compensation Insurance Fund; receives research support from the Centers for Disease Control and Prevention.

1) Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies2) e-Pearl topic: Neurologic manifestations of hereditary hemorrhagic telangiectasia3) Topic of the month: Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 1)This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Flaherty interviews Dr. Loch Macdonald about his paper on review and meta-analysis of 25 studies about the natural history of cavernous malformation. Dr. Adam Numis is reading our e-Pearl of the week about neurologic manifestations of hereditary hemorrhagic telangiectasia. Dr. Ted Burns interviews Dr. Gary Franklin about a Neurology Today story on the topic of the new Center for Disease Control guidelines on prescribing opioids (Part 1).DISCLOSURES: Dr. Flaherty serves on the scientific advisory board for DSMB member, I-DEF Trial (NINDS sponsored ICH treatment trial); has a patent pending, non-invasive CNS monitor; owns company stock as co-founder of SENSE Diagnostics, LLC (our product is currently investigational and not on the market); serves on the speakers' bureau of CSL Behring and Janssen; receives research support from American Heart Association, Pfizer Inc, Bristol-Myers Squibb, NIH and as Principal Investigator of a phase II, NINDS funded trial testing recombinant activated factor VII for treatment of intracerebral hemorrhage where study drug is supplied by Novo Nordisk.Dr. Macdonald serves as an editorial board member of Stroke, Journal of Neurosurgery, Neurosurgery, Journal of cerebral blood flow and metabolism, Neurocritical care, World Neurosurgery, Surgical Neurology International, Translational stroke research and Cerebrovascular diseases; treats unruptured aneurysm patients (1% effort); holds stock options in Edge Therapeutics, Inc; has a patent for treatment of delayed cerebral ischemia and subdural hemorrhage, intracranial drug delivery systems; receives research support from Canadian Institutes of Health Research, Brain Aneurysm Foundation, Heart and Stroke Foundation of Canada and Physicians Services Incorporated Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Franklin serves as an editorial board member of Neuroepidemiology; serves on the Levels of Evidence Team for Neurology®; is a consultant for the California State Compensation Insurance Fund; receives research support from the Centers for Disease Control and Prevention.

1) Variability in Physician Prognosis and Recommendations after Intracerebral Hemorrhage2) e-Pearl topic: Eye and facial findings in psychogenic non-epileptic seizures 3) Topic of the month: Neurology Today story about lead crisis in Flint exposing continuing risk to children nationwideThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Javier Provencio interviews Dr. Darin Zahuranec about his paper on variability in physician prognosis and recommendations after intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about eye and facial findings in psychogenic non-epileptic seizures. Dr. Ted Burns interviews Dr. Chris Holstege about a Neurology Today story on the topic of lead crisis in Flint exposes continuing risk to children nationwide: What neurologists should know and what they can do about it.DISCLOSURES: Dr. Provencio serves on the scientific advisory boards for Minnetronix, INC., Advanced Circulatory, Inc; serves on the data safety monitoring board for the ASTROH trial; Received honoraria and funding for travel from Bard, Inc.; serves as an editorial board member of Journal of Neuroimmunology; receives royalties from the publication of the book Family guide toSurviving the ICU; served on the board of directors of the Neurocritical Care Society; serves as President for the Ohio Chapter of the Society of Critical Care Medicine; receives research support From Bard Inc., Systemic Normothermia in ICH (SNICH), Crothermics INC. and the NIH.Dr. Zahuranec receives research support from Medtronic, Inc. and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.

1) Overdiagnosis of idiopathic intracranial hypertension2) e-Pearl topic: Neurologic manifestations of Hemolytic Uremic syndrome3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Valerie Biousse about her paper on overdiagnosis of idiopathic intracranial hypertension. Dr. Adam Numis is reading our e-Pearl of the week about neurologic manifestations of Hemolytic Uremic syndrome. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. James F. Meschia about the topic of what's on the horizon in endovascular stroke therapy. DISCLOSURES: Dr. Biousse serves as an editorial board member of American Journal of Ophthalmology and Journal of Neuro-ophthalmology; is a consultant for GenSight; receives royalties from the publication of the books Walsh and Hoyt's Clinical Neuro-Ophthalmology, Neuro-Ophthalmology Illustrated and from Up-to-Date; and receives research support for Research to Prevent Blindness.Dr. Numis serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Meschia serves as an editorial board member of Mayo Clinic Proceedings, Stroke and the European Journal of Neurology; receives research support from the NINDS for efforts devoted to the SiGN study.

1) Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF2) e-Pearl topic: Treatment of pediatric onset neuromyelitis optica3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Vincent Thijs about his paper on predictors for atrial fibrillation detection after cryptogenic stroke. Dr. Adam Numis is reading our e-Pearl of the week about treatment of pediatric onset neuromyelitis optica. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. Lee H. Schwamm about the topic of implications for stroke systems of care in endovascular stroke therapy. DISCLOSURES: Dr. Thijs serves as an Associate Editor for Acta Neurologica Belgica; serves as an editorial board member of Stroke and European Journal of Emergency Medicine; serves on the scientific advisory board for Sygnis Ax200 steering committee, Boehringer Ingelheim Belgium advisory board, Boehringer Ingelheim international advisory board, Medtronic steering committee of the REACT-AF trial; is a consultant for Boehringer Ingelheim, Pfizer Inc, Bayer Schering Pharma, AstraZeneca. Medtronic, Inc.; serves on the speakers bureau of Pfizer Inc, Boehringer Ingelheim and Medtronic, Inc.; received funding for travel or speaker honoraria from Medtronic, Inc.; Boehringer Ingelheim, Pfizer Inc, and Bayer Schering Pharma; receives research support from SYGNIS AG, Medtronic, Inc., Pfizer Inc, AstraZeneca, Boehringer Ingelheim and VIB Flanders Research Fund (FWO).Dr. Numis serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Schwamm serves on the scientific advisory board for CoAxia, Lundbeck Inc. DIAS 4 steering Committee, LifeImage and Medtronic, Inc.; serves as an editorial board member for Neurocritical Care, Stroke and Frontiers in TeleNeurology; receives royalties from the publication of the book Acute Ischemic Stroke: Imaging and Intervention, 2nd Edition; is a consultant for Lundbeck Inc. DIAS 4 steering Committee, LifeImage, Medtronic, Inc., and Massachusetts Department of Public Health; has a patent for Imaging system for obtaining quantitative perfusion indices. US Patent 6,542,769. 2003 Apr 1, The General Hospital Corporation assignee, Inventors: Schwamm LH and Sorensen AG; is the principal investigator of an investigator-initiated study of extended-window intravenous thrombolysis funded by the National Institutes of Neurological Disorders and Stroke (clinicaltrials.gov/show/NCT01282242) for which Genentech provides alteplase free of charge to Massachusetts General Hospital as well as supplemental per-patient payments to participating sites; is the chair of the AHA/ASA GWTG stroke clinical work group.

1) Neurology® Neuroimmunology & Neuroinflammation Journal: Basal ganglia T1-hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Dr. Eoin Flanagan about his Neurology: Neuroimmunology & Neuroinflammation paper on basal ganglia T1-hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Dr. Adam Numis is reading our e-Pearl of the week about genetic testing in facioscapulohumeral dystrophy. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of immunotherapy for autoimmune cerebellar ataxia. The participants had nothing to disclose except Drs. Numis, Burns and Ringel.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Ringel serves as editor of Neurology Today.NO CME WILL BE OFFERED THIS WEEK.

1) Infection, vaccination and childhood arterial ischemic stroke and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark McAllister interviews Dr. Heather Fullerton about her paper on infection, vaccination and childhood arterial ischemic stroke. Dr. Adam Numis is reading our e-Pearl of the week about Lafora body disease. In the next part of the podcast Dr. Ted Burns interviews Dr. Jim Bernat about his Neurology Today book review about “The Digital Doctor.” The participants had nothing to disclose except Drs. Fullerton, Numis, Burns and Bernat.Dr. Fullerton serves as an editorial board member of Stroke; serves on a DSMB for the NIH for clinical trials related to sickle cell disease and stroke; and receives research support from American Heart Association Established Investigator Award.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Bernat serves as an editorial board member of Neurocritical Care, Neurology Today, The Physician's Index for Ethics and Medicine and Multiple Sclerosis and Related Diseases; receives royalties from the publication of the books Ethical and Legal Issues in Neurology, Ethical Issues in Neurology, 3rd ed. and Palliative Care in Neurology.

1) Neurology® Genetics: Phenotypic and molecular analyses of primary lateral sclerosis and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Hitoshi Mitsumoto about his Neurology: Genetics paper on the phenotypic and molecular analyses of primary lateral sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about cerebral amyloid angiopathy-related inflammation. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of systemic exertion intolerance disease. The participants had nothing to disclose except Drs. Dimberg, Mitsumoto, Numis, Burns and Ringel.Dr. Dimberg serves as an editorial board member of Nerve and Muscle Junction Podcast.Dr. Mitsumoto is a consultant for Biogen Idec; receives research support from Avanir Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Biogen Idec and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Ringel serves as editor of Neurology Today.NO CME WILL BE OFFERED THIS WEEK.

1) Migraine and risk of stroke in older adults and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Teshamae Monteith about her paper on migraine and risk of stroke in older adults. Dr. Adam Numis is reading our e-Pearl of the week about neurosyphilis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of antemortem signatures of neurodegenerative proteinopathies. The participants had nothing to disclose except Drs. Southerland, Monteith, Numis, Espay and Josephs.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Monteith serves as an editorial advisory board member for Neurology Now; and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

1) Opioids for chronic non-cancer pain and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen Nadeau and Gary Franklin about their papers on opioids for chronic non-cancer pain and the policy behind prescribing them. Dr. Adam Numis is reading our e-Pearl of the week about vaccinations and seizures. In the next part of the podcast Dr. Alberto Espay interviews Dr. Virginia Lee about her Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of transmission of alpha-Synuclein in Parkinson disease: Pathogenesis and implications for therapy. The participants had nothing to disclose except Drs. Burns, Nadeau, Franklin, Numis, Espay and Lee.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Nadeau served on the DSMB for the National Institute of Neurological Disorders and Stroke and National Institute of Child Health and Human Development funded Interdisciplinary Comprehensive Arm Rehab Evaluation, DSMB ; served as an Associate Editor of the Journal of the International Neuropsychological Society; received honoraria and funding for travel for an International Neuropsychological Society meeting; received funding for travel for an American Neuropsychiatric Association meeting; receives royalties from the publication of the book The Neural Architecture of Grammar ; and receives research support from a VA Rehabilitation R&D Grant and University of Florida McKnight Brain Institute Brain and Spinal Cord Injury Research Trust Fund Grant.Dr. Franklin serves as an editorial board member of Neurology® Levels of Evidence Team and Neuroepidemiology; is a consultant for the California State Compensation Insurance Fund and receives research support from the Centers for Disease Control and Prevention (CDC).Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Lee serves as an editorial board member of Laboratory Investigation, Neurorehabilitation and Neural Repair, NeuroSignals, Neuron, Experimental Neurology, Science Magazine; receives research support from Ware Benaroya and the NIH; receives revenue for the following patent: "Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants" Penn G1120, Patent # 5,792,900.

1) CIDP diagnostic pit-falls and perception of treatment benefits and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Mauermann interviews Dr. Jeffrey Allen about his paper on chronic inflammatory demyelinating polyneuropathy diagnostic pit-falls and perception of treatment benefits. Dr. Adam Numis is reading our e-Pearl of the week about exam findings in hemifacial spasms. In the next part of the podcast Dr. Alberto Espay interviews Dr. Howard Weiner about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of immune mechanisms in neurologic diseases. The participants had nothing to disclose except Drs. Mauermann, Allen, Numis, Espay and Weiner.Dr. Mauermann receives research support from ISIS Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc. and the NIH.Dr. Allen is a consultant for AxelaCare and CSL Behring.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Weiner is a consultant for Biogen Idec, Novartis, Merck Serono, Sanofi-aventis, Teva Pharmaceutical Industries Ltd. and Therapix Biosciences Ltd.; served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis; receives research support from EMD, Merck Serono, National Multiple Sclerosis Society, and the NIH.

1) Aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erik Ensrud interviews Dr. Grete Andersen about her paper on aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy. Dr. Adam Numis is reading our e-Pearl of the week about non-invasive imaging of arterial dissection with MRI. In the next part of the podcast Dr. Alberto Espay interviews Dr. Stefan Pulst about his George C. Cotzias Lecture at the AAN Meeting about the topic of degenerative ataxias: From genes to therapies. The participants had nothing to disclose except Drs. Ensrud, Numis, Espay and Pulst.Dr. Ensrud serves on the data safety monitoring board for phase II trial of methotrexate in myastenia gravis; is a consultant for Skulpt/Convergence Medical Devices and FDA; received honoraria and funding for travel from Osler Institute; received funding for travel from American Association of Physical Medicine and Rehabilitation; and received honoraria from American Association of Neuromuscular and Electrodiagnostic Medicine.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Pulst serves as Editor-in-Chief of Current Genomics; serves as Editor of Neurology® Genetics; serves as an editorial board member of Journal of Cerebellum, NeuroMolecular Medicine, Continuum, Experimental Neurology, Neurogenetics, and Nature Clinical Practice Neurology; is author on patents re: Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Schwannomin-binding-proteins; and Compositions and methods for spinocerebellar ataxia; receives royalties from the publications of the books The Ataxias, Genetics in Neurology, Genetics of Movement Disorders, Neurogenetics, and Molecular Genetic Testing in Neurology, 2nd–5th ed.; serves on the speakers' bureau for Athena Diagnostics; receives research support from the NIH and the National Ataxia Foundation; receives license fee payments from Cedars-Sinai Medical Center; and has provided expert testimony in a medico-legal case.

1) Rising cost of multiple sclerosis drugs in the U. S. and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Jones interviews Dr. Daniel Hartung about his paper on the rising cost of multiple sclerosis drugs in the U. S. Dr. Adam Numis is reading our e-Pearl of the week about Walker-Warburg syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of treatment overview of immunotherapy for the immune-mediated myopathies. The participants had nothing to disclose except Drs. Jones, Hartung, Numis, Burns and Mammen.Dr. Jones has received personal compensation for attending consultant meetings for Biogen Idec, Novartis and Genzyme Corporation.Dr. Hartung serves on the data safety monitoring board for Kaiser Permanente Center for Health Research; is a consultant for Alkermes Inc.; receives research support from Alkermes Inc. and the Center for Disease Control and National Institute on Drug Abuse. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.

1) Looking ahead by looking back at practicing neurology and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Steven Ringel about his paper on looking ahead by looking back at practicing neurology. Dr. Adam Numis is reading our e-Pearl of the week about neurologic complications of heroin inhalation. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of inclusion body myositis. The participants had nothing to disclose except Drs. Ringel, Numis, Burns and Mammen.Dr. Ringel serves as Editor of Neurology Today.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.

1) Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Don Gilden about his paper on the prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Dr. Adam Numis is reading our e-Pearl of the week about unresponsive CIDP: Is it POEMS? In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of dermatomyositis. The participants had nothing to disclose except Drs. Gilden, Numis, Burns and Mammen.Dr. Gilden serves as an Senior Associate Editor for Journal of NeuroVirology; serves as an editorial board member of In Vivo, Journal of Virology, Scientific American Medicine, Virus Genes, Neurology and Journal of the Neurological Sciences; and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.

1) Dystonia: Five new things and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Brian Berman about his paper on five new things about dystonia. Dr. Adam Numis is reading our e-Pearl of the week about hereditary hemorrhagic telangectasia. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of immune-mediated necrotizing myopathy. The participants had nothing to disclose except Drs. Berman, Numis, Burns and Mammen.Dr. Berman serves on the Medical Advisory Boards for the Benign Essential Blepharospasm Research Foundation and the National Spasmodic Torticollis Association; has received funding for travel to conferences from Parkinson Study Group, American Neurological Association, Movement Disorder Society, Dystonia Medical Research Foundation, Benign Essential Blepharospasm Research Foundation; serves on the editorial board of Journal of Neurology and Neurophysiology; receives research support from the NIH, Dystonia Coalition, Dystonia Medical Research Foundation, Colorado Translational Research Imaging Center, University of Colorado Center for Neuroscience, The Dana Foundation, and the Benign Essential Blepharospasm Research Foundation. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.

1) Aspirin and intracerebral hemorrhage: Where are we now and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Reza Behrouz about his paper on where we are regarding aspirin use in relation to intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about POLG mutations in neurologic disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about some of his recent discoveries regarding pathogenic mechanism in autoimmune encephalitis, as well as current challenges facing autoimmune neurology. The participants had nothing to disclose except Drs. Southerland, Behrouz, Numis and Dalmau.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Behrouz serves as a Contributing Editor to Practical Neurology and as an Associate Editor for BioMed Central Neurology; and has participated in medico-legal cases.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Werner Poewe about his paper on olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD. Dr. Adam Numis is reading our e-Pearl of the week about Fragile X tremor ataxia syndrome. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about other recently described antibodies associated with autoimmune encephalitis. The participants had nothing to disclose except Drs. Poewe, Numis and Dalmau.Dr. Poewe has received consultancy and lecture fees from Abbott, AstraZeneca, Teva Pharmaceutical Industries Ltd, Novartis, GlaxoSmithKline, Boehringer Ingelheim, UCB, Orion Pharma Ltd., and Merck Serono in relation to clinical drug development programs for Parkinson disease; has received research support from the Michael J. Fox Foundation; receives royalties from the publications of the books: Therapeutics of Parkinson's disease and other movement disorders, Non-motor symptoms of Parkinson's disease and Parkinson-syndrome und andere Bewegungsstorungen.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Non-cognitive symptoms of early Alzheimer disease and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Catherine Roe about her paper on non-cognitive symptoms of early Alzheimer disease. Dr. Adam Numis is reading our e-Pearl of the week about cannabidiol in the treatment of epilepsy. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of NMDA receptor encephalitis. The participants had nothing to disclose except Drs. Burns, Roe, Numis and Dalmau.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Roe receives salary support from the NIH, the Longer Life Foundation, the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, The Farrell Family Research Fund, and F. Simmons and O. Mohan; receives research support from the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, the Longer Life Foundation, The Farrell Family Research Fund, and F. Simmons and O. Mohan.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Optimal achieved blood pressure in acute intracerebral hemorrhage and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Craig Anderson about his paper on the optimal achieved blood pressure in acute intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about neuropathy in Fabry disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of autoimmune and paraneoplastic encephalitis and how recent discoveries have changed our understanding of these disorders. The participants had nothing to disclose except Drs. Anderson, Numis and Dalmau.Dr. Anderson serves as an editorial board member of Stroke, Cerebrovascular Diseases, and Medical Journal of Australia; receives honoraria from serving on the scientific advisory board for Pfizer Inc and The Medicines Company; receives funding for travel from Takeda China and Covidien; and receives research support from the National Health and Medical Research Council (NHMRC) of Australia.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Her experiences and observations dealing with stroke recovery and rehabilitation and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Ms. Esmeralda Santiago about her experiences and observations dealing with stroke recovery and rehabilitation. Dr. Adam Numis is reading our e-Pearl of the week about variants of sporadic Creutzfeld-Jakob disease. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: tic status. The participants had nothing to disclose except Drs. Southerland, Addington and Frucht.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

1) Dietary treatment in adults with refractory epilepsy and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Pavel Klein about his paper on dietary treatment in adults with refractory epilepsy. Dr. Adam Numis is reading our e-Pearl of the week about intraventricular neurocysticercosis. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: dystonic storm. The participants had nothing to disclose except Drs. Klein, Numis and Frucht.Dr. Klein serves on the scientific advisory board for Eisai Inc., Sunovion Pharmaceuticals, Inc., Acorda Therapeutics.; serves on the speakers' boards of UCB, Eisai Inc., Sunovion Pharmaceuticals, Inc.; receives research support from UCB, SK Life Science, Inc., Marinus Pharmaceuticals, Inc. and Lundbeck Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

1) DPPX potassium channel antibody and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Oliver Tobin about his paper on the DPPX potassium channel antibody. Dr. Adam Numis is reading our e-Pearl of the week about cortical vein thrombosis. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: neuroleptic malignant syndrome. The participants had nothing to disclose except Drs. Burns, Numis and Frucht.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

1) Imaging prodromal Parkinson disease and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alberto Espay interviews Dr. Danna Jennings about her paper on imaging prodromal Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about distal hereditary neuropathies. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: serotonin syndrome. The participants had nothing to disclose except Drs. Espay, Jennings, Numis and Frucht.Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Jennings received speaker honoraria from Novartis; serves on the speaker board of UCB; receives research funding from Michael J. Fox Foundation, FORUM Pharmaceuticals, Concert Pharmaceuticals, Inc.; Omeros, Amgen, Abbvie, Merck Serono, Eli Lilly and Company, Avid Radiopharmaceuticals, Inc.; Navidea Biopharmaceuticals, Inc.; Eisai Inc., TauRx Therapeutics Ltd and Biogen Idec.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

Cerebral amyloid angiopathy-related inflammation and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Prachi Mehndiratta interviews Dr. Aaron Berkowitz about his paper on cerebral amyloid angiopathy-related inflammation. Dr. Adam Numis is reading our e-Pearl of the week about nasociliary reflex. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurocysticercosis, its common manifestations, investigations and treatment. The participants had nothing to disclose except Drs. Numis and Roos.Dr. Berkowitz received speaker honoraria from Stevens Institute of Technology and receives royalties from the publications of the books Clinical Pathophysiology Made Ridiculously Simple, MedMaster and The Improvising Mind, Oxford.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

1) Blood pressure management in stroke and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Ritvij Bowry about his paper on blood pressure management in stroke. Dr. Adam Numis is reading our e-Pearl of the week about Ondine's curse. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about Creutzfeldt–Jakob disease, its clinical symptoms, signs, natural course and treatment. The participants had nothing to disclose except Drs. Numis and Roos.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

1) Why brain death is considered death and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Drs. Chris Burkle and Eelco Wijdicks about their paper on why brain death is considered death. Dr. Adam Numis is reading our e-Pearl of the week about equine encephalitides. In the next part of the podcast Dr. Chenjie Xia interviews Dr. David Clifford about progressive multifocal leukoencephalopathy and neurologic care of patients with HIV/AIDS. The participants had nothing to disclose except Drs. Wijdicks, Numis and Clifford.Dr. Wijdicks served as Editor-in-Chief of Neurocritical Care and receives royalties from the publication of several books published by Oxford University Press.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clifford has served/serves on scientific advisory boards for Amgen, Biogen Idec/Quintiles, BMS, Genentech, Inc., Genzyme Corporation, Pfizer Inc, Millennium Pharmaceuticals, Inc. and Sanofi-aventis; received a speaker honorarium from Sun Pharmaceuticals; serves/has served as a consultant for Millennium Pharmaceuticals, Inc., Genzyme Corporation, Biogen Idec, IAS-USA, CMSC/ACTRIMS, ECTRIMS, Drinker, Biddle, Reath, Cytheris and Novartis; receives research support from Lilly, Roche, Alzheimer Association and the NIH (NIMH, NINR); and has provided consultation in medico-legal cases.

1) Clinical and ethical judgment and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Dan Larriviere interviews Dr. Ciro Ramos-Estebanez about his paper on clinical and ethical judgment. Dr. Adam Numis is reading our e-Pearl of the week about Brun's nystagmus. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Justin McArthur about the salient and clinically relevant features of HIV and its neurologic complications. The participants had nothing to disclose except Drs. Larriviere, Numis and McArthur.Dr. Larriviere serves as an Associate Editor of Continuum Audio; serves on the editorial advisory board of Neurology Today and receives speaker honoraria from American Association for the Advancement of Science.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. McArthur serves on the scientific advisory board of Relevare Pharmaceuticals LTD.; holds stock options in Relevare Pharmaceuticals LTD.; holds a patent for a device for thermal stimulation of small neural fibers with the World Intellectual Property Organization, International Publication Number WO 03/040672 A2, medical device for treatment of ulnar neuropathy. UlnarGuard ™ (JHU Ref: 4545) and immunophilin ligand treatment of antiretroviral toxic neuropathy (Provisional application number 60/466,650).

1) Growth hormone treatment for childhood short stature and risk of stroke in early adulthood and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Cyrus Boelman interviews Dr. Emmanuel Touze about his paper on growth hormone treatment for childhood short stature and risk of stroke in early childhood. Dr. Adam Numis is reading our e-Pearl of the week about LG-1 antibodies in limbic encephalitis. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Don Levy about approaches of Integrative Medicine practitioners to patient care. The participants had nothing to disclose except Dr. Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

1) A clinical pathologic study of depressive symptoms and cognitive decline in old age and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Robert S. Wilson about his paper on depressive symptoms and cognitive decline in old age. Dr. Adam Numis is reading our e-Pearl of the week about ictal syncope. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Tieraona Low Dog about complementary alternative medicine therapies using supplements for treatment of headaches. The participants had nothing to disclose except Drs. Burns, Wilson and Numis. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Wilson serves as a Consulting Editor of Aging, Neuropsychology and Cognition, Psychology and Aging, and Neuropsychology; is a consultant for Pain Therapeutics, Inc.; and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Untreated brain arteriovenous malformations: Patient level meta-analysis of hemorrhage predictors and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeremy Lanford interviews Dr. Helen Kim about her paper on untreated brain arteriovenous malformations. Dr. Adam Numis is reading our e-Pearl of the week about spinal epidural abscesses. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Remy Coeytaux about complementary alternative medicine to chronic pain and integrative medicine approaches. The participants had nothing to disclose except Drs. Coeytaux and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Coeytaux is a consultant for Samueli Institute and receives research support from the NIH.

1) Palliative care and neurology: Time for a paradigm shift and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Bragg interviews Dr. Benzi Kluger about his paper on palliative care and neurology: Time for a paradigm shift. Dr. Adam Numis is reading our e-Pearl of the week about intravascular B-cell lymphoma. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Pushpa Narayanaswami about complementary alternative medicine therapies for patients with multiple sclerosis. The participants had nothing to disclose except Drs. Kluger, Numis, and Narayanaswami.Dr. Kluger serves as an editorial board member of Frontiers in Movement Disorders; received speaker honoraria from Teva Pharmaceutical Industrials Ltd., Parkinson's Association of the Rockies and National Parkinson's Foundation; receives research support from the US Army Research Laboratory and US Army Research Office, Veterans Affairs Medical Center CRICC Program, Michael J. Fox Foundation, University of Colorado Hospital Clinical Effectiveness and Patient Safety Program and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Narayanaswami serves as an editorial board member of Neurology® Level of Evidence Review Team; is a consultant for Blue Cross Blue Shield of Massachusetts, Pharmacy and Therapeutics Committee, Advanced Medical and Boston Clinical Research Institute; performs EMG in her clinical practice (35% effort); receives research support from Merz Pharmaceuticals, Inc., Solstice Pharma and AHRQ; received research support from the NIH.

1) Factors associated with recovery from acute optic neuritis in multiple sclerosis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Tanuja Chitnis about her paper on factors associated with recovery from acute optic neuritis in multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about tanycytic ependymal tumors. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Bacterial meningoencephalitides. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Chitnis is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis, Sanofi-aventis; receives research support from Merck Serono and Novartis in the form of Independent Investigator Awards, National Multiple Sclerosis Society. the Peabody Foundation and the Guthy-Jackson Charitable Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

1) Abnormal thalamic function in patients with vestibular migraine and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Jen interviews Dr. Gioacchino Tedeschi about his paper on abnormal thalamic function in patients with vestibular migraine. Dr. Adam Numis is reading our e-Pearl of the week about Gerstmann-Straussler-Scheinker syndrome. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Lyme disease. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos.Dr. Jen serves as a Section Editor for Experimental Brain Research; serves as an Associate Editor for Frontiers in Neuro-otology; receives research support from the FDA.Dr. Tedeschi receives speaker honoraria from Novartis, Schwarz Pharma AG, UCB, Lundbeck Inc., GlaxoSmithKline and AbbVie.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

1) Anti-agrin autoantibodies in myasthenia gravis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Arthur Melms about his paper on anti-agrin autoantibodies in myasthenia gravis. Dr. Adam Numis is reading our e-Pearl of the week about myopathy masquerading as myasthenia. In the next part of the podcast Dr. Chenjie Xia interviews Drs. Maria Nagel and Don Gilden about neurology and infectious diseases: Viral meningoencephalitides. The participants had nothing to disclose except Drs. Burns, Melms, Numis, Nagel and Gilden.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Melms performs clinical procedures as Professor of Neurology and Neurorehabilitation at the University of Erlangen, Germany (20%) and is clinical director of a privately owned neurological rehabilitation hospital (80%); clinical research is supported by the Ernst Freiberger Foundation, Berlin, Germany; received speaker honoraria from GlaxoSmithKline; received research support from German Research Agency, Collaborative Research Center 685, Immunotherapy, and the Gemeinützige Hertie Foundation, Frankfurt/Main, Germany.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Nagel receives research support from the NIH.Dr. Gilden serves as Senior Associate Editor of Journal of NeuroVirology; serves as an editorial board member of In Vivo, Journal of Virology; Scientific American Medicine, Virus Genes, Neurology Journal, receives research support from the NIH.

1) AAN paper on efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Suski interviews Dr. Barbara Koppel about the AAN paper on efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders. Dr. Adam Numis is reading our e-Pearl of the week about myoclonic astatic epilepsy. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Greg Bergey about epilepsy therapeutics: Beyond medications for the refractory patient. The participants had nothing to disclose except Drs. Koppel, Numis and Bergey.Dr. Koppel serves as an editorial board member of Clinical Neurology.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bergey was an expert witness in medicolegal activity over the past two years and receives research support from the NIH.

1) Migraine trait symptoms in migraine with and without aura and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Sowell interviews Dr. Tim Jürgens about his paper on migraine trait symptoms in migraine with and without aura. Dr. Adam Numis is reading our e-Pearl of the week about idiopathic normal pressure hydrocephalus. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Elinor Ben-Menachem about epilepsy therapeutics: Vigabatrin. The participants had nothing to disclose except Drs. Jürgens, Numis and Ben-Menachem.Dr. Jurgens serves as an editorial board member of ISRN Pain, serves as Visiting Editor of the Journal of Headache and Pain; is a consultant for Autonomic Technologies, Inc.; received speaker honoraria from Allergan, Inc., Pfizer Inc, MSD (commercial), Autonomic Technologies, Inc., DAGFA (non-profit), Kinderhospiz Sternenbrucke (non-commercial), received funding for Travel from MSD (commercial), Autonomic Technologies, Inc., DAGFA (non-profit), Kinderhospiz Sternenbrucke (non-commercial), Deutsche Migrane- und Kopfschmerzgesellschaft (non-commercial),) Deutsche Schmerzgesellschaft (non-commercial); serves as a board member of Deutsche Migrane- und Kopfschmerzgesellschaft; receives research support from Allergan, Inc. and Deutsche Migrane- und Kopfschmerzgesellschaft.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ben-Menachem serves as Editor of Acta Neurologica Scanidnavica; receives funding for travel from Eisai Inc., UCB, ElectroCore Medical, LLC.

1) Skin nerve a-synuclein deposits being a biomarker for idiopathic Parkinson disease and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Vincenzo Donadio about his paper on skin nerve ?-synuclein deposits being a biomarker for idiopathic Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about cognitive impairment in pediatric multiple sclerosis. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Nathan Fountain about epilepsy therapeutics: Lacosamide. The participants had nothing to disclose except Drs. Fountain and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.

1) Fingolimod after natalizumab and the risk of short-term relapse and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Vilija Jokubaitis about her paper on fingolimod after natalizumab and the risk of short-term relapse. Dr. Adam Numis is reading our e-Pearl of the week about cardiac cephalgia. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Madeline Fields about epilepsy therapeutics: Clobazam. The participants had nothing to disclose except Drs. Keegan, Jokubaitis and Numis.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Jokubaitis received funding for travel to speak at a conference from Novartis, receives research support from MSBase Foundation and National Health and Medical Research Council.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Rolandic epilepsy has little effect on adult life 30 years later and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Drs. Carol and Peter Camfield about their paper on how rolandic epilepsy had little effect on adult life 30 years later. Dr. Adam Numis is reading our e-Pearl of the week about lower cranial nerve dysfunction. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Jacqueline French about epilepsy therapeutics: Perampanel. There is different intro music, "Goofy Vocal Groove" by Dave Girtsman in this podcast. The song may be found at http://freemusicarchive.org/music/Dave_Girtsman/Silly_Songs/11_-_dave_girtsman_-_goofy_vocal_groove_kzz01_vbr. The original work was not changed ii any way and is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License. The participants had nothing to disclose except Drs. Fountain, Peter Camfield, Numis and French.Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.Dr. Peter Camfield serves as an editorial board member of Journal of Child Neurology and Pediatric Neurology Epileptic Disorders Journal.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. French serves as an Associate Editor for Epilepsia; serves as an editorial board member of Lancet Neurology, Neurology Today, Epilepsy Currents; serves on the scientific advisory board for Electrocore, Epilepsy Therapy Project, UCB, Eisai Inc., SK Corporation, Marinus, Upsher-Smith Laboratories, Inc., Sunovion Inc., Vertex Pharmaceuticals, Novartis, Epilepsy Study Consortium; received paid travel to present findings at scientific meetings, present at investigators meetings attend advisory boards or give lectures from Acorda, UCB, Eisai, Inc., Johnson and Johnson, Upsher-Smith Laboratories, Inc., Novartis, Pfizer Inc, Eli Lilly and Company, LCGH, Vertex Pharmaceuticals, Supernus, Marinus Pharmaceuticals, Inc., SK Corporation; receives research support from Eisai, Inc., UCB, SK Corporation, Valeant Pharmaceuticals International, Upsher-Smith Laboratories, Inc., Vertex Pharmaceuticals, Pfizer Inc, Marinus Pharmaceuticals, Brain Sentinal, Epilepsy Research Foundation, The Milken Foundation, The Epilepsy Study Consortium and the NIH.

1) High dose midazolam infusion for refractory status epilepticus and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Jan Claassen about his paper on high dose midazolam infusion for refractory status epilepticus. Dr. Adam Numis is reading our e-Pearl of the week about genetic testing in early onset epileptic encephalopathies. In the next part of the podcast Dr. Matt Barrett interviews Dr. Vicki Shanker about clinical approach to non-Parkinson disease tremor. The participants had nothing to disclose except Drs. Claassen and Numis. Dr. Claassen serves as an editorial board member of Neurocritical Care.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Drs. Riley Bove and Philip De Jager about their paper on the influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women. Dr. Adam Numis is reading our e-Pearl of the week about parechovirus and neurologic disease. In the next part of the podcast Dr. Binit Shah interviews Dr. Anthony Lang about non-neurodegenerative causes of parkinsonism - drug-induced; structural: NPH, stroke, tumor; psychogenic. The participants had nothing to disclose except Drs. Burns, Bove, De Jager, Numis and Lang.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Bove receives research support from Partners Healthcare, National Multiple Sclerosis Society and the NIH.Dr. De Jager serves as an editorial board member of the Journal of Neuroimmunology; serves on the scientific advisory board for Teva Neuroscience, Genzyme/Sanofi; receives speakers' honoraria from Biogen Idec and Source Healthcare Analytics, LLC; receives research support from Biogen Idec, GlaxoSmithKline, Genzyme/Sanofi, Vertex Pharmaceuticals and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Lang served as an advisor for Abbott, Abbvie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec, Boerhinger-Ingelheim, Ceregene, Medtronic, Inc, Merck Serono, Novartis, NeuroPhage Pharmaceuticals, Teva Pharmaceutical Industries Ltd, UCB.; received research support from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, National Parkinson Foundation, Parkinson Society Canada, Tourette Syndrome Association, W. Garfield Weston Foundation; received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, Cambridge University Press; served as an expert witness in cases related to the welding industry.

1) Guideline on assessment and management of psychiatric disorders in individuals with multiple sclerosis and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Sarah Minden about AAN paper on assessment and management of psychiatric disorders in individuals with multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about airplane headache. In the next part of the podcast Dr. Binit Shah interviews Dr. Melissa Armstrong about diagnosis, management and prognosis of atypical parkinsonian disorders. The participants had nothing to disclose except Drs. Keegan, Minden, Numis and Armstrong.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Minden received honoraria and travel reimbursement for meetings from Pfizer Inc, Merck Serono, Genentech, Inc., Novartis, and Avanir Pharmaceuticals; received research support from the National Multiple Sclerosis Society, the Center for Mental Health Services, and the Substance Abuse and Mental Health Services Administration; holds stock options in Merck Serono, Schering-Plough Corp, and GlaxoSmithKline.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Armstrong serves on the Level of Evidence Review Team for Neurology®; is an evidence-based guideline methodology consultant for the AAN; receives research support from Abbvie as local sub-investigator; received a 2011 Movement Disorders Society travel Scholarship to the MDS International Congress; and in 2010-2011 was partially funded by a Edmond J. Safra Fellowship at Toronto Western Hospital.

1) Effect of head impacts on diffusivity measures in collegiate contact sport athletes and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Noah Kolb interviews Dr. Thomas McAllister about his paper on effect of head impacts on diffusivity measures in collegiate contact sport athletes. Dr. Adam Numis is reading our e-Pearl of the week about recurrent rhabdomyolysis. In the next part of the podcast Dr. Matt Barrett interviews Dr. Dan Weintraub about management of neuropsychiatric manifestations of Parkinson disease. The participants had nothing to disclose except Drs. McAllister, Numis and Weintraub.Dr. McAllister receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Weintraub serves as an editorial board member of Movement Disorders Journal; serves on the scientific advisory board of Pfizer Inc, Teva Pharmaceutical Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Eli Lilly and Company, Biogen Idec, Lundbeck Inc., UCB, Bristol-Myers Squibb, CHDI Foundation, Inc, ADCS; receives fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson disease; receives commercial funding for travel from Teva Pharmaceutical Industries Ltd.; gave expert testimony for defense in 2012-2013 in lawsuit related to impulse control disorders in Parkinson disease; receives research support from Novartis, Michael J. Fox Foundation for Parkinson's Research and the NIH.

1) Pretreatment cognitive deficits and treatment effects in childhood epilepsy and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nick Brenton interviews Dr. Tracy Glauser about his paper on pretreatment cognitive deficits and treatment effects in childhood epilepsy. Lara Marcuse talks about being diagnosed with cancer after listening to Ted Burns discuss his diagnosis in our September 3 podcast. Dr. Adam Numis is reading our e-Pearl of the week about ophthalmologic findings in neurocysticercosis. In the next part of the podcast Dr. Mark Keegan interviews Dr. Douglas Goodin about interferons and copaxone in multiple sclerosis. The participants had nothing to disclose except Drs. Glauser, Numis, Keegan, and Goodin.Dr. Glauser serves on the scientific advisory board for AssureRx Health, Inc.; serves on the speakers' bureau and receives honoraria from Supernus Pharmaceuticals; receives royalties from the publication of the book Pediatric Epilepsy; receives royalty payments for optimization of drug selection software algorithms, AssureRx Health, Inc.; holds stock options in AssureRx Health, Inc.; has patents for optimization of drug selection software algorithms, neurocognitive computing algorithms and suicide prediction algorithms; is a consultant for Supernus Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Eisai, Inc., UCB, Lundbeck Inc., Questcor Pharmaceuticals, Inc, Upsher-Smith, AssureRx Health, Inc.; receives license fees from AssureRx Health, Inc. for optimization of drug selection software algorithms and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Goodin receives research support from Novartis; had travel costs reimbursed for occasional community lectures, symposia and/or academic talks sponsored by Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd., Merck Serono. Genzyme and Novartis.

1) Dementia management quality measures and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Amy Sanders about her paper on dementia management quality measures. Dr. Adam Numis is reading our e-Pearl of the week about Leber's hereditary optic neuropathy. In the next part of the podcast Dr. Mark Keegan interviews Dr. Alasdair Coles about alemtuzumab treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Burns, Sanders, Numis, Keegan, and Coles.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Sanders is a member of a federal advisory committee (MEDCAC); received honoraria for serving on peer-review panels from the CMMI and PCORI; and research support from the Einstein CTSA Grant from the National Center for Research Resources, a component of the NIH and NIH roadmap for Medical Research; loan repayment support from LRP/NIA. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Coles is a co-editor of Advances in Clinical Neuroscience and Rehabilitation; serves on the scientific advisory board for the Multiple Sclerosis Society of GB & NI, International Society for Neuroimmunology, Genzyme Corporation steering committee, UK Advisory Board, Merck Serono; is a consultant and receives speakers' honoraria from Nil, Merck Serono, Genzyme Corporation, Bayer Schering Pharma; and has a patent for IL-21 as a marker of autoimmunity after alemtuzumab treatment.

1) Vagus nerve stimulation for the treatment of epilepsy and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Antel Patel interviews Dr. George Morris about his paper on vagus nerve stimulation for the treatment of epilepsy. Dr. Adam Numis is reading our e-Pearl of the week about vitamin B6 and epilepsy. In the next part of the podcast Dr. Mark Keegan interviews Dr. Robert Fox about dimethylfumarate for multiple sclerosis. The participants had nothing to disclose except Drs. Patel, Morris, Numis, Keegan, and Fox.Dr. Patel serves as Book editor for the Journal of Child Neurology; receives research support from UCB and Eisai Inc.Dr. Morris performs clinical care involving vagus nerve stimulation (5% effort) in his practice; serves on the speakers' bureaus of UCB, Cyberonics, Lundbeck, Inc.; is a consultant for UCB, Cyberonics, Lundbeck, Inc.; receives honoraria from UCB, Cyberonics, Lundbeck. Inc; receives research support from UCB, Cyberonics, Lundbeck. Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Fox serves as an editorial board member of Neurology and Multiple Sclerosis Journal; serves on the scientific advisory board for Biogen Idec, Novartis; is a consultant for Allozyne, Avanir, Biogen Idec, Novartis, Questcor, EMD Serono, and Teva Pharmaceutical Industries Ltd.; receives research support from Novartis, National MS Society and NIH.

1) Cognitive speed of processing training in Parkinson disease and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Jerri Edwards about her paper on cognitive speed of processing training in Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about stiff person syndrome. In the next part of the podcast Dr. Mark Keegan interviews Dr. Jeffrey Cohen about fingolimod therapy for multiple sclerosis. The participants had nothing to disclose except Drs. Edwards, Numis, Keegan, and Cohen.Dr. Edwards receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Cohen received consulting fees from Novartis and Teva Pharmaceutical Industries Ltd.; receives royalties from the publication of the book Multiple Sclerosis Therapeutics, 4th edition; received research support from the Department of Defense and the NIH.

1) Migraine and structural changes in the brain and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Messoud Ashina about his paper on migraine and structural changes in the brain. Dr. Adam Numis is reading our e-Pearl of the week about manganese neurotoxicity. In the next part of the podcast Dr. Mark Keegan interviews Dr. Paul O' Connor about teriflunomide for the treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Ashima, Numis, Keegan, and O'Connor.Dr. Ashina serves as an Associate Editor of Cephalalgia; serves on the scientific advisory board for The Journal of Headache and Pain; is a consultant for ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received honoraria for lecturing from Allergan Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. O'Connor serves on the scientific advisory boards of Novartis Fingolimod Steering Committee, Sanofi-aventis Teriflunomide Steering Committee, BRAVO (laquinimod) study DMC-chairman, Genetech, Inc. Roche, Acetelion Pharmaceuticals Ltd, Receptos, Inc; received honoraria for attending two Advisory board meetings; served on the editorial advisory board for the MS Journal; serves as a consultant for Biogen Idec, Merck Serono, is currently a consultant for Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Novartis; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec, and from the MS Society of Canada as National Scientific and Clinical Advisor.

1) Risk factors for dementia with Lewy bodies and 2) Topic of the month: Frontotemporal degeneration. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Geldmacher interviews Dr. Brendon Boot about his paper on risk factors for dementia with Lewy bodies. Dr. Adam Numis is reading our e-Pearl of the week about reversible cerebral vasoconstriction syndrome. In the next part of the podcast Dr. Brandy Matthews focuses her interview with Dr. Bill Seeley about therapeutics and future directions in frontotemporal degeneration. The participants had nothing to disclose except Drs. Geldmacher, Numis, Matthews and Seeley.Dr. Geldmacher serves as an editorial board member of Brain Injury; serves on a Data Safety Committee for GlaxoSmithKline; received research support from Baxter International Inc., Elan Corporation, Eisai Inc.; received honoraria for consulting from Abbvie, Janssen Alzheimer Immunotherapy, and Baxter International Inc. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Matthews receives research support from the NIH.Dr. Seeley serves as an editorial board member for Annuals of Neurology; served on the scientific advisory board for Bristol-Myers Squibb; is a consultant for Summer Street Research Partners; received speaker honorarium from Novartis Korea; received research support from the John Douglas French Alzheimer's Disease Foundation, Consortium for Frontotemporal Dementia Research; Tau Consortium, James S. McDonnell Foundation, Alzheimer's Disease Drug Foundation, Association for Frontotemporal Dementia and National Institute on Aging.

1) Electronic media in neurology education and 2) Topic of the month: Frontotemporal degeneration. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Shaheen Lakhan about his paper on electronic media in neurology education. Dr. Adam Numis is reading our e-Pearl of the week about hemifacial spasm. In the next part of the podcast Dr. Brandy Matthews focuses her interview with Dr. Bill Seeley about diagnostic testing and genetics in frontotemporal degeneration. The participants had nothing to disclose except Drs. Lakhan, Numis, Matthews and Seeley.Dr. Lakhan serves on the editorial team for the Neurology® Resident and Fellow Section, serves as Associate Editor for BMC Research Notes and Journal of Medical Case Reports, BioMed Central, serves as an editorial board member of International Archives of Medicine, BioMed Central; serves on the scientific advisory board for OA Pain Medicine, OA Publishing London, Nanotechnology Research Foundation, National Science & Technology Education Partnership, International Physicians Advisory Council, International Cancer Advocacy Network; is a consultant for Global Neuroscience Initiative Foundation and receives research support from Global Neuroscience Initiative Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Matthews receives research support from the NIH.Dr. Seeley serves as an editorial board member for Annuals of Neurology; served on the scientific advisory board for Bristol-Myers Squibb; is a consultant for Summer Street Research Partners; received speaker honorarium from Novartis Korea; received research support from the John Douglas French Alzheimer's Disease Foundation, Consortium for Frontotemporal Dementia Research; Tau Consortium, James S. McDonnell Foundation, Alzheimer's Disease Drug Foundation, Association for Frontotemporal Dementia and National Institute on Aging.

1) An index to identify stroke-related versus incidental patent foramen ovale in cryptogenic stroke and 2) Topic of the month: Frontotemporal degeneration. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. David Kent about his paper on using an index to identify stroke-related versus incidental patent foramen ovale in cryptogenic stroke. Dr. Adam Numis is reading our e-Pearl of the week about superior quadrantopia. In the next part of the podcast Dr. Brandy Matthews focuses her interview with Dr. Bill Seeley about clinical presentations and bedside evaluation in frontotemporal degeneration. The participants had nothing to disclose except Drs. Kent, Numis, Matthews and Seeley.Dr. Kent is a consultant for WL Gore Associates and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Matthews receives research support from the NIH.Dr. Seeley serves as an editorial board member for Annuals of Neurology; served on the scientific advisory board for Bristol-Myers Squibb; is a consultant for Summer Street Research Partners; received speaker honorarium from Novartis Korea; received research support from the John Douglas French Alzheimer's Disease Foundation, Consortium for Frontotemporal Dementia Research; Tau Consortium, James S. McDonnell Foundation, Alzheimer's Disease Drug Foundation, Association for Frontotemporal Dementia and National Institute on Aging.

1) Optic nerve head component responses of multifocal electroretinogram in MS and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Beau Bruce interviews Drs. Teresa and Elliot Frohman about their paper on optic nerve head component responses of multifocal electroretinogram in MS. Dr. Adam Numis is reading our e-Pearl of the week about Terson's syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. John Trojanowski about progressive accumulation of tau pathology in patients with Alzheimer disease and how it occurred in a stereotypical manner. The participants had nothing to disclose except Drs. Bruce, Teresa Frohman, Eliot Frohman, Numis, Espay, and Trojanowski.Dr. Bruce is a consultant for Kaiser Permanente of Georgia for the CDC Vaccine Safety Datalink; receives research support from Novartis, Pfizer Inc, TEVA Pharmaceutical Industries, Ltd and the NIH; and was a recipient of the Practice Research Fellowship.Dr. Teresa Frohman serves as an editorial board member of National Multiple Sclerosis Society; is a consultant for Acorda, Novartis; serves on the speakers' bureau of Acorda Therapeutics, Inc., Novartis; receives royalties from the publication of Up-to-Date; received funding for travel from Acorda Therapeutics Inc., Novartis; received research support from the National Multiple Sclerosis Society and the NIH.Dr. Elliot Frohman is a consultant for TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics, Inc., Novartis, Genzyme Corporation, Abbott; serves on the speakers' bureau of TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis; receives royalties from the publication of Up-to-Date; and received funding for travel from TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Trojanowski serves as an Associate Editor for Alzheimer & Dementia; received research support from The Marian S. Ware Alzheimer Program, Benaroya and the NIH; holds 14 patents that may accrue revenue: US Patent 5,281,521, issued 25 Jan 1994: US Patent 5,580,898, issued 3 Dec 1996; US Patent 5,601,985, issued 11 Feb 1997; US Patent 5,733,734, issued 31 Mar 1998; US Patent 5,792,900, issued 11 Aug 1998; US Patent 5,849,988, issued 15 Dec 1998: US Patent 6,214,334, issued 10 Apr 2001; US Patent 6,358,681, issued 19 Mar 2002; US Patent 6,727,075, issued 27 Mar 2004; US Patent 7,011,827, issued 14 Mar 2006; Penn 0652, K1828, filed 5 Aug 1998; Penn L1986, Filed 13 Nov 1998; Penn R3868 (UPN-4439), filed 28 Feb 2005 and Penn S-4018, DB&R 46406- 217282, filed 22 Nov 2005: Treatment of Alzheimer's and Related Diseases with an Antibody and may accrue revenue in the future on patents submitted by the University of Pennsylvania as co-Inventor and received revenue from the sale of Avid to Eli Lilly and Company as co-inventor on imaging related patents submitted by the University of Pennsylvania while receiving research support from the NIH, Bristol-Myers Squibb, AstraZeneca and several non-profits.

1) Depressive symptoms and white matter dysfunction in retired NFL players with concussion history and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Christopher Giza interviews Dr. John Hart about his paper on depressive symptoms and white matter dysfunction in retired NFL players. Dr. Adam Numis is reading our e-Pearl of the week about ice-cream headache. In the next part of the podcast Dr. Alberto Espay interviews Drs. Ron Postuma and Brad Boeve about clinicopathologic correlations in 172 cases of REM sleep behavior disorder. The participants had nothing to disclose except Drs. Giza, Hart, Numis, Espay, Postuma and Boeve.Dr. Giza serves on the data safety monitoring board for LAbiomed Institute at Harbor-UCLA Medical Center; is a consult for NHL Player's Association; serves on the speakers' bureau for the Medical Education Speakers Network; receives royalties from the publication of the book Neurological Differential Diagnosis: A prioritized approach; received funding for travel to Major League Soccer Concussion Committee meeting, California State Athletic Commission Meetings and NCAA meeting; receives research funding from NIH, UCLA faculty grants, Thrasher Research Foundation, NFL Charities, Today's and Tomorrow's Children Fund, Richie's Fund and NCAA, and gave expert testimony on several mediocolegal cases.Dr. Hart serves as an editorial board member of Neurocase, Journal of Innovative Optical Health, World Journals of Radiology and Psychiatry, Frontiers in Neuropsychiatric Imaging and Stimulation; receives royalties from the publication of the book Neural Basis of Semantic Memory; receives research support from the Department of Defense, Alzheimer's Association, RGK Foundation and NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Postuma serves on the scientific advisory board for TEVA Pharmaceutical Industries Ltd; serves as an editorial board member of Movement Disorders Journal and Journal of Caffeine Research; receives honoraria from Allergan, Inc., Novartis, TEVA Pharmaceutical Industries Ltd; receives research support from the Canadian Institute of Health Research, Parkinson Society of Canada, Fonds de Recherche de la Sante Quebec, Weston Foundation and Drummond Foundation.Dr. Boeve has served as an investigator for clinical trials sponsored by Cephalon, Inc., Allon Pharmaceuticals and GE Healthcare; receives royalties from the publication of a book Behavioral Neurology of Dementia; received honoraria from the American Academy of Neurology; serves on the scientific advisory board of the Tau Consortium and receives research support from the National Institute on Aging and the Mangurian Foundation.

1) Guideline update: Evaluation and management of concussion in sports and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Christopher Giza about this guideline update on evaluation and management of concussion in sports. Dr. Adam Numis is reading our e-Pearl of the week about anti -MuSK antibody myasthenia gravis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Merit Cudkowicz about her plenary session on ALS pathways to treatments. The participants had nothing to disclose except Drs. Goodkin, Giza, Numis, Espay and Cudkowicz.Dr. Goodkin serves as an editorial board member of Neurology and Surgical Neurology International; receives royalties from Up-to-Date for co-authorship of The Choking Game and other strangulation activities in children and adolescents; receives research support from the NIH.Dr. Giza serves on the data safety monitoring board for LAbiomed Institute at Harbor-UCLA Medical Center; is a consult for NHL Player's Association; serves on the speakers' bureau for the Medical Education Speakers Network; receives royalties from the publication of the book Neurological Differential Diagnosis: A prioritized approach; received funding for travel to Major League Soccer Concussion Committee meeting, California State Athletic Commission Meetings and NCAA meeting; receives research funding from NIH, UCLA faculty grants, Thrasher Research Foundation, NFL Charities, Today's and Tomorrow's Children Fund, Richie's Fund and NCAA, and gave expert testimony on several mediocolegal cases.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Cudkowicz is a consultant for TEVA Pharmaceutical Industries Ltd., Cytokinetics, Biogen Idec; receives research support from Muscular Dystrophy Association, Amyotrophic Lateral Sclerosis Association, American Telemedicine Association and the NIH.

1) Creation of the AAN Global Health Section and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Amy Lee about her paper on the creation of the AAN Global Health Section. Dr. Adam Numis is reading our e-Pearl of the week about Tullio phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jerome Posner about receiving the 2013 President's Award at the AAN Meeting and discussing his lecture on the importance of teaching and mentoring in neurology. The participants had nothing to disclose except Drs. Mateen, Numis, Espay and Posner.Dr. Mateen has consulted for the World Health Organization, Global Polio Eradication Initiative, and Caritas.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Posner serves as an editorial board member on Up-to-Date; receives royalties from the publications of the books Diagnosis of stupor and coma and Neurologic complications of cancer; receives royalty payments, technology/inventions from Athena diagnostics.

1) Exposure to stroke belt on incident stroke and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Virginia Howard about her paper on exposure to the stroke belt on incident stroke in adulthood. Dr. Adam Numis is reading our e-Pearl of the week about Neuro-Behcet's disease. In the next part of the podcast Dr. Brett Kissela focuses his interview with Dr. Chelsea Kidwell about the MR Rescue trial. The participants had nothing to disclose except Drs Howard, Numis, Kissela and Kidwell.Dr. Howard serves on DSMB for NIH-NIDA; is a consultant for NIH review committees and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring. and provides medico-legal reviews.Dr. Kidwell serves as an editorial board member of Stroke, Neurocritical Care Journal, Journal of Neuroimaging and Stroke Research and Treatment; and receives research support from Baxter and NIH.

1) Atrial fibrillation and unexplained stroke and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Paul Cotter about his paper on incidence of atrial fibrillation and unexplained stroke. Dr. Adam Numis is reading our e-Pearl of the week about LGI-1 antibodies in limbic encephalitis. In the next part of the podcast Dr. Brett Kissela interviews Drs. Opeolu Adeoye and Art Pancioli about the CLEAR-ER trial. The participants had nothing to disclose except Drs Cotter, Numis, Kissela and Adeoye.Dr. Cotter receives research support from the UK National Institute for Health Research, Cambridge biomedical Research Center and Clinical Research Fellowship.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring. and provides medico-legal reviews.Dr. Adeoye received honoraria for serving on the speakers' bureau of Genentech, Inc. and receives research support from the NIH.

1) Human herpes 6 virus encephalitis and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Jen interviews Dr. Mina Bhanushali and Sarah Kranick about their paper on human herpes 6 virus encephalitis and stem cell transplantation. Dr. Adam Numis is reading our e-Pearl of the week about ictal syncope. In the next part of the podcast Dr. Brett Kissela interviews Dr. Clay Johnston about CHANCE trial. All the participants have disclosures.Dr. Jen serves as an Associate Editor of Frontiers in Neuro-otology and Section Editor of Experimental Brain Research and receives research support from the FDA.Ms. Kranick is a staff member of the National Institute of Health.Dr. Bhanushali Is an employee of the National Institute of Health.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring. and provides medico-legal reviews.Dr. Johnston serves as Co-Editor-in-Chief of Journal Watch Neurology; serves as Vice Editor of Annals of Neurology; is co-holder of patent on the RNA panel to identify TIA and risk stratify; Stryker Neurovascular, Boston Scientific, Kaiser-Permanente, NCRR/NCATS, CTSA, AHA/ASA, Bugher Award and the NIH and provided expert testimony in legal proceedings for GlaxoSmithKline.

1) NMO spectrum and MS brain lesion and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Lucy Matthews about her paper on seropositive NMO spectrum disorder and MS brain lesion distribution. Dr. Adam Numis is reading our e-Pearl of the week about intravascular B-cell lymphoma. In the next part of the podcast Dr. Brett Kissela interviews Dr. Joseph Broderick about IMS III trial. All the participants have disclosures.Dr. Keegan serves as Chief Editor for eMedicine; is a consultant for Bionest and Novartis. Dr. Matthews receives research support from UK Medical Research Council and is funded by the Clinical Research Training Fellow ship.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring. and provides medico-legal reviews.Dr. Broderick has served as a consultant for PhotoThera-DSMB for NEST III study and Genentech, Inc.; receives funding for travel to NIH study section and NIH-sponsored meetings, TST meeting and national meeting by Covidien and RISS Summit by Genentech and as part as invited Visiting Professor; has received research support from Boehringer Ingelheim, Concentric, EKOS, Genentech, Inc, Johnson & Johnson, Novo Nordisk, Schering-Plough Corp, Merck, and the NIH as part of NINDS funded clinical trials.